Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 9/2017

01-09-2017 | Original Article

Poly(ADP-ribosylated) proteins in mononuclear cells from patients with type 2 diabetes identified by proteomic studies

Authors: Alessandra Giorgi, Italo Tempera, Giorgia Napoletani, Diego Drovandi, Cinzia Potestà, Sara Martire, Elisabetta Mandosi, Tiziana Filardi, M. Eugenia Schininà, Susanna Morano, Maria d’Erme, Bruno Maras

Published in: Acta Diabetologica | Issue 9/2017

Login to get access

Abstract

Aims

In diabetes, hyperglycemia increases reactive oxygen species that induce DNA damage and poly(ADP-ribose)polymerase activation. The aim of this study is to characterize the proteomic profile and the role of poly(ADP-ribosylation) in patients with type 2 diabetes.

Methods

A proteomic platform based on 2DE and MALDI-ToF spectrometry was applied to peripheral blood mononuclear cells obtained from two different cohorts in which diabetic (n = 14) and normoglycemic patients (n = 11) were enrolled.

Results

Proteomic maps identified WD repeat protein, 78-kDa glucose-regulated protein precursor and myosin regulatory light chain 2, as unique proteins in diabetic patients; vimentin, elongation factor 2, annexin A1, glutathione S-transferase P, moesin and cofilin-1 as unique in the normoglycemic; and calreticulin, rho GDP-dissociation inhibitor 2, protein disulfide isomerase and tropomyosin alpha-4-chain as differentially expressed between the two cohorts. An enrichment in PARylation in diabetic patients was observed in particular, affecting GAPDH and α-Enolase leading to a decrease in their enzymatic activity.

Conclusions

As the GAPDH and α-Enolase are involved in energy metabolism, protein synthesis and DNA repair, loss of their function or change in their activity can significantly contribute to the molecular mechanisms responsible for the development of type 2 diabetes. These data along with the proteomic profile associated with the disease may provide new insight into the pathophysiology of type 2 diabetes.
Literature
1.
Guariguata L (2013) Contribute data to the 6th edition of the IDF Diabetes Atlas. Diabetes Res Clin Pract 100(2):280–281CrossRefPubMed
2.
Abdul-Ghani MA, Tripathy D, DeFronzo RA (2006) Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29(5):1130–1139CrossRefPubMed
3.
Shakeel M (2015) Recent advances in understanding the role of oxidative stress in diabetic neuropathy. Diabetes Metab Syndr 9:373–378CrossRefPubMed
4.
Velloso LA, Eizirik DL, Cnop M (2013) Type 2 diabetes mellitus—an autoimmune disease? Nat Rev Endocrinol 9(12):750–755CrossRefPubMed
5.
Mabley JG et al (2002) NFkappaB1 (p50)-deficient mice are not susceptible to multiple low-dose streptozotocin-induced diabetes. J Endocrinol 173(3):457–464CrossRefPubMed
6.
Xu B et al (2008) PARP activation and the alteration of vasoactive factors and extracellular matrix protein in retina and kidney in diabetes. Diabetes Metab Res Rev 24(5):404–412CrossRefPubMed
7.
Schreck R, Rieber P, Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 10(8):2247–2258PubMedPubMedCentral
8.
Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141–179CrossRefPubMed
9.
Schaefer-Graf UM et al (2000) Patterns of congenital anomalies and relationship to initial maternal fasting glucose levels in pregnancies complicated by Type 2 and gestational diabetes. Am J Obstet Gynecol 182(2):313–320CrossRefPubMed
10.
de Murcia G, Menissier de Murcia J (1994) Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 19(4):172–176CrossRefPubMed
11.
12.
Gupte R, Liu Z, Kraus WL (2017) PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Genes Dev 31(2):101–126CrossRefPubMedPubMedCentral
13.
Bai P, Canto C (2012) The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab 16(3):290–295CrossRefPubMed
14.
Bai P et al (2015) Poly(ADP-ribose) polymerases as modulators of mitochondrial activity. Trends Endocrinol Metab 26(2):75–83CrossRefPubMed
15.
16.
17.
18.
Sodhi RK, Singh N, Jaggi AS (2010) Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications. Vasc Pharmacol 53(3–4):77–87CrossRef
19.
Vida A et al (2017) Metabolic roles of poly(ADP-ribose) polymerases. Semin Cell Dev Biol 63:135–143CrossRefPubMed
20.
Soriano FG, Virag L, Szabo C (2001) Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med (Berl) 79(8):437–448CrossRef
21.
Szabo C et al (1997) Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J Clin Invest 100(3):723–735CrossRefPubMedPubMedCentral
22.
Szabo C et al (2006) Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of Type 2 diabetic Leprdb/db mice. Diabetes 55(11):3004–3012CrossRefPubMed
23.
Tempera I et al (2005) Poly(ADP-ribose)polymerase activity is reduced in circulating mononuclear cells from Type 2 diabetic patients. J Cell Physiol 205(3):387–392CrossRefPubMed
24.
Dwinovan J et al (2017) Proteomic analysis reveals downregulation of housekeeping proteins in the diabetic vascular proteome. Acta Diabetol 54(2):171–190CrossRefPubMed
25.
Puthanveetil P et al (2012) Diabetes triggers a PARP1 mediated death pathway in the heart through participation of FoxO1. J Mol Cell Cardiol 53(5):677–686CrossRefPubMed
26.
Obrosova IG et al (2004) Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53(3):711–720CrossRefPubMed
27.
Long CA et al (2013) Poly-ADP-ribose-polymerase inhibition ameliorates hind limb ischemia reperfusion injury in a murine model of Type 2 diabetes. Ann Surg 258(6):1087–1095CrossRefPubMed
28.
Pieper AA et al (1999) Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci USA 96(6):3059–3064CrossRefPubMedPubMedCentral
29.
Rinaldo C et al (2012) HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. Mol Cell 47(1):87–98CrossRefPubMed
30.
Yang M, Kahn AM (2006) Insulin-stimulated NADH/NAD+ redox state increases NAD(P)H oxidase activity in cultured rat vascular smooth muscle cells. Am J Hypertens 19(6):587–592CrossRefPubMed
31.
Whiting GC et al (2002) Purification of native alpha-enolase from Streptococcus pneumoniae that binds plasminogen and is immunogenic. J Med Microbiol 51(10):837–843CrossRefPubMed
32.
Butterfield DA et al (2006) Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer’s disease: an initial assessment. J Alzheimers Dis 10(4):391–397CrossRefPubMed
33.
Bai P (2015) Biology of poly(ADP-ribose) polymerases: the factotums of cell maintenance. Mol Cell 58(6):947–958CrossRefPubMed
34.
Teodoro-Morrison T et al (2013) GRP78 overproduction in pancreatic beta cells protects against high-fat-diet-induced diabetes in mice. Diabetologia 56(5):1057–1067CrossRefPubMed
35.
Fang L et al (2015) Analysis of the human proteome in subcutaneous and visceral fat depots in diabetic and non-diabetic patients with morbid obesity. J Proteom Bioinform 8(6):133–141
36.
Pietrani NT et al (2014) Annexin A1 concentrations is decreased in patients with diabetes Type 2 and nephropathy. Clin Chim Acta 436:181–182CrossRefPubMed
37.
Sharma M et al (2016) Association of glutathione-S-transferase with patients of Type 2 diabetes mellitus with and without nephropathy. Diabetes Metab Syndr 10(4):194–197CrossRefPubMed
38.
Du X et al (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112(7):1049–1057CrossRefPubMedPubMedCentral
39.
Sirover MA (1999) New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta 1432(2):159–184CrossRefPubMed
40.
Chuang DM, Hough C, Senatorov VV (2005) Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. Annu Rev Pharmacol Toxicol 45:269–290CrossRefPubMed
41.
Morgenegg G et al (1986) Glyceraldehyde-3-phosphate dehydrogenase is a nonhistone protein and a possible activator of transcription in neurons. J Neurochem 47(1):54–62CrossRefPubMed
42.
Singh R, Green MR (1993) Sequence-specific binding of transfer RNA by glyceraldehyde-3-phosphate dehydrogenase. Science 259(5093):365–368CrossRefPubMed
43.
Meyer-Siegler K et al (1991) A human nuclear uracil DNA glycosylase is the 37-kDa subunit of glyceraldehyde-3-phosphate dehydrogenase. Proc Natl Acad Sci USA 88(19):8460–8464CrossRefPubMedPubMedCentral
44.
Abd Elmageed ZY et al (2012) The poly(ADP-ribose) polymerases (PARPs): new roles in intracellular transport. Cell Signal 24(1):1–8CrossRefPubMed
45.
Hara MR, Cascio MB, Sawa A (2006) GAPDH as a sensor of NO stress. Biochim Biophys Acta 1762(5):502–509CrossRefPubMed
46.
Byun YS et al (2015) Poly(ADP-ribose) polymerase inhibition improves corneal epithelial innervation and wound healing in diabetic rats. Invest Ophthalmol Vis Sci 56(3):1948–1955CrossRefPubMed
47.
Andrabi SA et al (2014) Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc Natl Acad Sci USA 111(28):10209–10214CrossRefPubMedPubMedCentral
48.
Lu N et al (2014) Nitrative modifications of alpha-enolase in hepatic proteins from diabetic rats: the involvement of myeloperoxidase. Chem Biol Interact 220:12–19CrossRefPubMed
49.
De Rosa V et al (2015) Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat Immunol 16(11):1174–1184CrossRefPubMedPubMedCentral
Metadata
Title
Poly(ADP-ribosylated) proteins in mononuclear cells from patients with type 2 diabetes identified by proteomic studies
Authors
Alessandra Giorgi
Italo Tempera
Giorgia Napoletani
Diego Drovandi
Cinzia Potestà
Sara Martire
Elisabetta Mandosi
Tiziana Filardi
M. Eugenia Schininà
Susanna Morano
Maria d’Erme
Bruno Maras
Publication date
01-09-2017
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 9/2017
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-017-1013-y

Other articles of this Issue 9/2017

Acta Diabetologica 9/2017 Go to the issue

Short Communication

Team management of gestational diabetes: a training experience

Review Article

Epicardial adipose tissue: at the heart of the obesity complications

Original Article

Improving diabetes care at primary care level with a multistrategic approach: results of the DIAPREM programme

Original Article

Effect of lifestyle improvement program on the biomarkers of adiposity, inflammation and gut hormones in overweight/obese Asian Indians with prediabetes

Erratum

Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas

Original Article

GLIS3 rs7020673 and rs10758593 polymorphisms interact in the susceptibility for type 1 diabetes mellitus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits